Mural Oncology's (MURA) shares jumped more than 160% in recent trading Tuesday after the company said it is discontinuing all clinical development of nemvaleukin alfa and plans to immediately start exploring strategic alternatives.
The move follows the review of data from its phase 2 ARTISTRY-6 trial in melanoma, which failed to achieve the primary endpoint, and previously announced adverse results from the phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer, the Ireland-based clinical-stage immuno-oncology company said.
The company has engaged Lucid Capital Markets LLC as financial adviser for the exploration of strategic alternatives, which would include an offer for or other acquisition of the company, merger, or business combination. The company also said it will reduce its workforce by roughly 90%.
As of Dec. 31, 2024, the company had approximately $144.4 million of cash and cash equivalents, and marketable securities.
Price: 3.02, Change: +1.99, Percent Change: +193.30
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。